In AD, both genetic and acquired barrier damage were proven to be able to activate KCs, and cytokine production (TSLP, IL-33, IL-25) by KCs initiates DC activation and, consequently, type 2 adaptive immune response and inflammation [14,19]. This evidence concerns the gene TBCE and Alzheimer disease.